• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Statin therapy does not prevent osteoporotic fractures [JUPITER trial]

byAnees DaudandJames Jiang
December 1, 2014
in Endocrinology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Based on the results of the trial, there was no difference in the rates of osteoporotic fractures between the group receiving statin therapy compared to the group receiving placebo.

2. Additionally, rising levels of high-sensitivity C-reactive protein (hs-CRP), which is an inflammatory marker related to cardiovascular disease, was not associated with higher incidence of fractures.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Osteoporosis has a significant burden of disease, especially in an aging population. Inflammation plays a major role in not just cardiovascular disease, but also osteoporosis. Statin therapies, which have been mainstays in reducing mortality related to cardiovascular disease, have also been studied in prevention of osteoporosis. This study, the data for which comes from the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, sought to determine whether statin therapy was associated with a lower risk of fractures and if higher hs-CRP levels were associated with a greater risk for developing osteoporosis. The results of the study suggested that there was no difference in the rates of fractures between the group receiving stain therapy compared to the one receiving placebo. Additionally, rising levels of hs-CRP did not have any relationship with incidence of fractures.

The JUPITER study has strong internal validity. The results are also generalizable to previously healthy men and women without elevated cholesterol levels. Moreover, the endpoint of osteoporotic fractures was selected a priori. Weaknesses of the study include the relatively short follow-up period, which may not have been able to detect positive outcomes related to osteoporosis, and the fact that a single, fixed-dose of statin was used. Given the negative result of the trial, questions have been raised as to whether the study was adequately powered to detect smaller differences in first fracture rates.

Click to read the study, published today in JAMA Internal Medicine

Relevant Reading: Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial

RELATED REPORTS

Treat-to-target approach non-inferior to high-dose statin therapy in patients with coronary artery disease

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

#VisualAbstract: Vitamin D supplementation is not preventative for statin-associated muscle symptoms or statin discontinuation

In-Depth [randomized controlled trial]: The data for this study comes from the randomized, double-blind, placebo-controlled, multinational JUPITER trial. One of the pre-specified secondary endpoints of the trial was development of an incident fracture. Relevant inclusion criteria included men and women over ages 50 and 60 years old, respectively, with no history of cardiovascular disease or diabetes mellitus. Exclusion criteria included alcohol abuse, cancer, lupus, severe arthritis, inflammatory bowel disease, use of postmenopausal hormone therapy, or long-term oral glucocorticoid use.

In total, 17,802 participants were included in the study analysis, and the follow-up period was up to five years. The primary endpoint of the original study was related to a cardiovascular event, but an incident fracture was one of the pre-specified secondary endpoints of the study. Study participants were screened from 2003 to 2006, and the study ended in 2008. The investigators performed a multivariable regression model to account for co-morbid conditions and demographic differences. The results of the study showed that the incidence of fracture in the statin and placebo groups were 1.20 and 1.14 per 100 person-years, respectively (HR 1.06; 95%CI 0.88-1.28), showing that there was no significant difference between the two groups. Male and female sex also did not show any differences. There was also no difference between rising hs-CRP and risk of fractures (HR for each unit increase in hs-CRP 1.06; 95%CI 0.94-1.20).

More from this author: Basic life support associated with greater survival in cardiac arrest, Cardiac biomarkers unnecessarily ordered in emergency departments, Secondhand smoke exposure counseling may be insufficient amongst cardiology inpatients, Dabigatran linked with more major bleeds, fewer intracranial hemorrhages vs warfarin, Non-invasive ventilation linked with lower mortality in COPD exacerbations

Image: CC/Nevit Dilmen

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: osteoporosisstatin
Previous Post

Moderate and late preterm birth increases cerebral palsy risk

Next Post

Midlife diabetes associated with cognitive decline

RelatedReports

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study
Cardiology

Treat-to-target approach non-inferior to high-dose statin therapy in patients with coronary artery disease

March 10, 2023
Romosozumab significantly increases bone mineral density in postmenopausal women
Chronic Disease

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

January 30, 2023
#VisualAbstract: Double sequential external defibrillation and vector-change defibrillation improve outcomes in patients with refractory ventricular fibrillation
StudyGraphics

#VisualAbstract: Vitamin D supplementation is not preventative for statin-associated muscle symptoms or statin discontinuation

December 8, 2022
Ivabradine ineffective in stable coronary artery disease [SIGNIFY trial]
Cardiology

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

November 22, 2022
Next Post
Midlife diabetes associated with cognitive decline

Midlife diabetes associated with cognitive decline

2 Minute Medicine Rewind November 23 – November 30, 2014

2 Minute Medicine Rewind November 23 – November 30, 2014

CXCL13 shows potential as anti-NMDA receptor encephalitis biomarker

CXCL13 shows potential as anti-NMDA receptor encephalitis biomarker

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 72- and 36-hour fever prevention post-cardiac arrest equivalent in preventing mortality
  • Spirituality may promote mental health recovery for people with schizophrenia in Southeast Asia
  • #VisualAbstract: Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options